Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Postviral Olfactory Loss With Glucocorticoids, Ginkgo biloba, and Mometasone Nasal Spray

Treatment of Postviral Olfactory Loss With Glucocorticoids, Ginkgo biloba, and Mometasone Nasal... ORIGINAL ARTICLE Treatment of Postviral Olfactory Loss With Glucocorticoids, Ginkgo biloba, and Mometasone Nasal Spray Beom Seok Seo, MD; Hyun Jong Lee, MD; Ji-Hun Mo, MD; Chul Hee Lee, MD; Chae-Seo Rhee, MD; Jeong-Whun Kim, MD, PhD Objective: To analyze the efficacy of treating postviral The mean (SD) BTT score changes were 1.4 (2.2) in the olfactory loss with glucocorticoids, Ginkgo biloba, and mo- monotherapy group and 2.2 (2.9) in the combination metasone furoate nasal spray. therapy group (P=.22). The mean (SD) CCSIT score changes were 0.9 (1.7) in the monotherapy group and Design: Randomized trial. 1.9 (2.7) in the combination therapy group (P=.11). On the BTT, the treatment response (defined as a score in- Setting: Academic research. crease of 3) rates were 32% (9 of 28) in the mono- therapy group and 37% (16 of 43) in the combination Patients: Seventy-one patients who were diagnosed as therapy group (P=.66), and the odds ratio was 1.25 (95% having postviral olfactory loss. confidence interval, 0.46-3.42). On the CCSIT, the treat- ment response rates were 14% (4 of 28) in the mono- Main Outcome Measures: All patients underwent ol- therapy group and 33% (14 of 43) in the combination factory function http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Otolaryngology - Head & Neck Surgery American Medical Association

Treatment of Postviral Olfactory Loss With Glucocorticoids, Ginkgo biloba, and Mometasone Nasal Spray

Download PDF
5 pages

Loading next page...
 
/lp/american-medical-association/treatment-of-postviral-olfactory-loss-with-glucocorticoids-ginkgo-VMI2CeYy90

References (24)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6181
eISSN
2168-619X
DOI
10.1001/archoto.2009.141
pmid
19841338
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Treatment of Postviral Olfactory Loss With Glucocorticoids, Ginkgo biloba, and Mometasone Nasal Spray Beom Seok Seo, MD; Hyun Jong Lee, MD; Ji-Hun Mo, MD; Chul Hee Lee, MD; Chae-Seo Rhee, MD; Jeong-Whun Kim, MD, PhD Objective: To analyze the efficacy of treating postviral The mean (SD) BTT score changes were 1.4 (2.2) in the olfactory loss with glucocorticoids, Ginkgo biloba, and mo- monotherapy group and 2.2 (2.9) in the combination metasone furoate nasal spray. therapy group (P=.22). The mean (SD) CCSIT score changes were 0.9 (1.7) in the monotherapy group and Design: Randomized trial. 1.9 (2.7) in the combination therapy group (P=.11). On the BTT, the treatment response (defined as a score in- Setting: Academic research. crease of 3) rates were 32% (9 of 28) in the mono- therapy group and 37% (16 of 43) in the combination Patients: Seventy-one patients who were diagnosed as therapy group (P=.66), and the odds ratio was 1.25 (95% having postviral olfactory loss. confidence interval, 0.46-3.42). On the CCSIT, the treat- ment response rates were 14% (4 of 28) in the mono- Main Outcome Measures: All patients underwent ol- therapy group and 33% (14 of 43) in the combination factory function

Journal

JAMA Otolaryngology - Head & Neck Surgery – American Medical Association

Published: Oct 1, 2009

There are no references for this article.